Update on BCR signaling inhibitors in CLL from ASH 2015

Dr. Joshua Brody, MD – @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses an update on BCR signaling inhibitors in CLL at ASH 2015